Copaxone’s Tombstone? 2014 Could Be Year Generic Launches, Momenta Says
FDA “has not to date had any questions that would indicate our application is off track,” CEO Wheeler says as Momenta and partner Sandoz gear up for the launch.
FDA “has not to date had any questions that would indicate our application is off track,” CEO Wheeler says as Momenta and partner Sandoz gear up for the launch.